Stockscreener 앱 받기
1.26
4.55%
-0.06
시간 외 거래:
1.29
0.03
+2.38%
전일 마감가:
$1.32
열려 있는:
$1.25
하루 거래량:
2.80M
Relative Volume:
1.32
시가총액:
$258.30M
수익:
$12.87M
순이익/손실:
$-114.34M
주가수익비율:
-1.4573
EPS:
-0.8646
순현금흐름:
$-79.23M
1주 성능:
-32.98%
1개월 성능:
-22.22%
6개월 성능:
-37.62%
1년 성능:
-53.68%
1일 변동 폭
$1.205
$1.32
1주일 범위
$1.17
$1.95
52주 변동 폭
$1.17
$4.32
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
명칭
Taysha Gene Therapies Inc
전화
(214) 612-0000
주소
3000 PEGASUS PARK DRIVE, DALLAS
TSHA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
1.26 | 258.30M | 12.87M | -114.34M | -79.23M | -0.8646 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-04-09 | 개시 | Piper Sandler | Overweight |
| 2023-02-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-03-09 | 개시 | Robert W. Baird | Outperform |
| 2022-03-01 | 개시 | Wells Fargo | Overweight |
| 2022-02-18 | 개시 | SMBC Nikko | Outperform |
| 2021-12-16 | 개시 | Guggenheim | Buy |
| 2021-07-16 | 개시 | Needham | Buy |
| 2021-06-24 | 개시 | Truist | Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-06-09 | 개시 | Wedbush | Outperform |
| 2021-06-08 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-11 | 재개 | Jefferies | Buy |
| 2021-02-24 | 개시 | William Blair | Outperform |
| 2021-01-05 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-19 | 개시 | Goldman | Buy |
| 2020-10-19 | 개시 | Jefferies | Buy |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Taysha Gene Therapies Inc 주식(TSHA)의 최신 뉴스
At $1.32 Price, Taysha Gene Therapies Inc (TSHA) Is Sitting And Waiting - stocksregister.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet - Benzinga
Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges By Investing.com - Investing.com South Africa
Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges - Investing.com India
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Acquires 111,989 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Is Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts? - Insider Monkey
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.63 - Defense World
Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment By Investing.com - Investing.com South Africa
Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment - Investing.com Australia
Taysha Gene Therapies (TSHA) to Release Earnings on Tuesday - Defense World
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha's Latest Stock Option Grants: Key Details for Institutional Investors - StockTitan
TSHA FY2025 EPS Forecast Raised by Cantor Fitzgerald - Defense World
Needham & Company LLC Reaffirms Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Chardan Capital Reiterates Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies’ Positive Earnings Call Highlights - TipRanks
Positive Outlook for Taysha Gene Therapies: Buy Rating Backed by FDA Progress and Strong Financial Position - TipRanks
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Call Transcript - MSN
Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Taysha Gene Therapies Reports 2024 Financial Results - TipRanks
Positive Outlook on Taysha Gene Therapies: Promising Developments and Financial Stability - TipRanks
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Taysha Gene Therapies reports FY24 EPS (36c) vs (96c) last year - TipRanks
Taysha Gene Therapies Inc Reports Full Year 2024 EPS of -$0.36 a - GuruFocus.com
Earnings call transcript: Taysha Gene's Q4 2024 reports narrower loss, stock dips - Investing.com
Earnings call transcript: Taysha Gene’s Q4 2024 reports narrower loss, stock dips - Investing.com India
Taysha Gene Therapies, Inc. SEC 10-K Report - TradingView
Can Taysha's Gene Therapy for Rett Syndrome Deliver? Key Safety Milestone Reached as Cash Extends to 2026 - StockTitan
Taysha Gene Therapies Inc (TSHA) Q4 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Taysha Gene Therapies (TSHA) Projected to Post Earnings on Wednesday - Defense World
Taysha Gene Therapies to Release Full-Year 2024 Financial - GlobeNewswire
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 - The Manila Times
Gene Therapy Pioneer Taysha Readies Crucial 2024 Financial DisclosureHere's When - StockTitan
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Average Price Target from Brokerages - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by SG Americas Securities LLC - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 1.3%Time to Buy? - MarketBeat
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Critical Analysis: Creative Medical Technology (NASDAQ:CELZ) vs. Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies Inc (TSHA) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Taysha Gene Therapies Inc [TSHA] Records 50-Day SMA of $1.9835 - Knox Daily
Taysha's Strategic Move: 491K Stock Options Awarded to Secure Top Industry Talent - StockTitan
Taysha Gene Therapies Inc (TSHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):